Idéal Investisseur
Français English
CAC 40 : Market open
8 083,02 pts
-0.43%


Last updated : 15/09/2026 - 16h58
🏠 Home   ➤    Stock news

Valneva Shares at €2.70: Oversold RSI After a 38% Drop in Three Months

The stock of the Nantes-based vaccine specialist rose by 2.5% this Tuesday compared to the previous day, yet it does not offset a quarter of significant losses. Valneva is trading at €2.70, reflecting a nearly 38% decline over three months, in a Parisian market trending upwards with the CAC 40 up by 0.79% during the session.


Valneva Shares at €2.70: Oversold RSI After a 38% Drop in Three Months

Current Market Position of Valneva

Valneva's stock price stands at €2.70 in mid-afternoon, up 2.5% from the previous day's close of €2.64. This slight increase remains marginal compared to recent trends: the stock has lost 37.61% over three months and 2.52% over a year. The technical support identified at €2.58 held during recent sessions, partly explaining today's modest rebound. The RSI, a momentum indicator, is at 29, marking the threshold of the generally established oversold zone at 30. This level indicates that selling pressure has been particularly intense in recent weeks. Furthermore, the current price is significantly below the 50-day moving average (€4.00) and the 200-day average (€3.88), confirming a medium-term downward trend. At €2.70, the stock is in the lower part of the Bollinger Bands, at 33% of the range between the lower bound (€1.52) and the upper bound (€5.09).

Upcoming Financial Events and Sector Performance

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
Before 9 AM every morning Euronext data AI-powered analysis

Investors will gain a first glimpse of visibility on May 7, when Valneva is set to publish its first-quarter 2026 results. This event will be followed by the annual general meeting scheduled for June 1. These milestones could help clarify the operational and financial trajectory of the group, in a context where the stock has lost more than a third of its value in three months. On a European sector level, the session is mixed: Sanofi is up by 1.17% while UCB is down by 0.18%. Valneva's negative beta (-0.21) indicates an inverse correlation with the market, giving the stock an atypical profile within the Paris stock exchange. The half-year results, expected on August 13, will be another crucial milestone to assess the group's ability to stabilize its valuation.



Sector Pharmacie et biotechnologies Vaccins et laboratoires de recherche


Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext

Context

Period
  • Period: S1 2026
Key reported figures
  • Revenue: 65,8 millions d'euros
  • Quarterly revenue: 65,8 millions d'euros
  • Revenue growth: -32,6 %
  • EBITDA: -39,8 millions d'euros
  • Net income: -63,3 millions d'euros
Guidance from the release
  • Malgré l'impact négatif persistant du contexte géopolitique sur les voyages, Valneva a confirmé ses perspectives pour 2026
Risks mentioned
  • Impact négatif persistant du contexte géopolitique sur les voyages affectant les ventes de produits
  • Dépendance commerciale élevée envers les livraisons d'IXIARO au Département américain de la Défense avec calendrier incertain
  • Recentrage stratégique d'IXCHIQ sur les marchés endémiques affectant les perspectives commerciales du vaccin contre le chikungunya
Opportunities identified
  • Décisions réglementaires attendues pour le candidat vaccin LB6V contre la maladie de Lyme dans les 12 prochains mois
  • Amélioration attendue des marges brutes au second semestre après impact d'éléments non récurrents au S1 2026
  • Bénéfices futurs de l'initiative de restructuration visant à réduire la consommation de trésorerie et optimiser les opérations
Outlook / guidance
  • Expected revenue: 147,5 millions d'euros

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
Avant 9h00 1000+ inscrits 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours